Investment Q&A

Q: Good morning,
I understand that Valens announced a deal yesterday where "underwriters have agreed to purchase, on a bought deal basis, 10,613,207 units of the company at a price of $2.65 per unit." The stock plunged 25% yesterday on the news to $2.16. I am sad to admit that I am ignorant to why this stock dropped so much on the news - any insights you can provide? Also, I bought this stock with a 5-10 year hold plan - still a good long-term company?

Q: Could you comment on WELL's quarterly results as well as your general outlook of the stock? Thanks in advance. - Jeff

Q: Hi Peter and Staff

Looking at my health care basket, I have a couple of losers in it VEEV and VTRS.

I have had losers I regretted selling and losers I wish I had not wasted opportunity cost on.......I am fine doing either....Do you think the risk/reward of selling either or both of these to top up ABBV,PFE,SYK or JNJ would be a good move in the long run ignoring how many positions I have or should I hang on. If a sale is suggested which order would you top up the 4 stocks mentioned.

Thanks for all you do
Dennis

Q: Hi folks
BMO Investorline's chart for DXCM is completely different than your chart? Can you explain please. Your chart shows huge jump in price on about March 25th. Is this correct? Is there still room for gain? Would you BUY now? My Health sector weight is 4.55% which is down from its high due to the market of course. (ZTS, PFE, GH, VEEV, BNTX)
Much thanks for keeping me well on track through the ups and downs for about 8 years now..I recommend you often.

Q: What is your current view on Bausch Health Companies? It looks like a good price now. Or, would you prefer any of other names in health care now such as PFE, LLY or JNJ? Already hold ABBV and MRK.

Q: TH TMX

Any Hope for this company. / Should I move on /Your comment on last quarter please. Thanks RAK.

Q: Hello 5i team,

Need an opinion on resizing my healthcare investment.

I hold GILD, ABBV, PFE in our portfolio; ABBV & PFE are doing well while GILD is barely breaking even. Your thought in replacing GILD with JNJ or go to IHI - a medical devices ETF.

Thank you !

Q: Hi Folks,
I've held GILD in my TFSA now for a couple of years and I'm down 27%, time to let it go. I also hold ABBV, PFE and MDT all performing well - can you suggest a replacement for GILD - looking for a company paying a dividend with some growth. Appreciate your suggestion.
Thanks

Q: Hello 5i team,
I was wondering if you listened in on the phone conference with knight therapeutics? If so, is there anything they plan on doing that would move the stock in the coming year?

Are you still doing reports on GUD in the future?

Thank You,
Andrew

Q: SIS dropped 0.63 the day after Q results.Then the following day (3/25) it was up $1.05 to $17.92.The G & M reported as follows.NA sees significant long term upside with exceptional backlog,a$23.50 target price & a outperform rating. Desjardins says it is too cheap to ignore with a $25.50 TP & Buy. Any other news to prompt the big increase,& u comments.Txs for u usual great services & views.

Q: Is there an overlap in their business? Whats your view on both these stocks and which one would you prefer.

Q: Hi - 2 part question: Over the next year or so, what would be your top selections for US healthcare stocks? Second, what sub sector of US Healthcare do you like the most over next year?
Thank you as always.

Q: hi folks, thoughts on Q results & guidance for Knight Ther, gud/t....Buy/Hold/Sell....thanks as always, jb. Piedmont QC

Q: I am interested in purchasing MPW or NWH.UN . Which one would be considered more secure with respect to dividend payouts ? Joe

Q: What is your take on the quarterly results?

Q: Noticed the option volume surge on this company any idea if they have some news pending

Q: Can you comment on the recent rise in this stock?
Would you continue to hold?

Q: Hi it was me under standing that well results were supposed to be out yesterday have you heard any thing
Regards
Stan

Q: Good morning 5i

I am wavering between these two. I already own some abbivie. But I hesitate because it has shot up recently. I know you favour it. But I have seen several people lately, today Brian Acre, leaning towards bmy. Here is the reasoning of one such person:

The company has a strong pipeline of new drugs, but also a lot of patent expirations for its big existing drugs coming up, which means the company has to effectively rotate its portfolio of revenue-producing drugs in the coming years. To offset that risk, it is priced very cheaply, with a single-digit price/earnings ratio and a solid dividend yield. I think the current price offers a good accumulation zone.

I am wondering about your different approaches. Would it be that you favour growth more and they are looking for safe income?
Thanks as always

Q: I was wondering if you could provide any commentary on the newly spun-out company, ZImVie (formerly from Zimmer Biomet). I am familiar with their dental products - they are quite good, and focus primarily on the implant space (including implant fixtures, prosthetic components for tooth replacement and bone regeneration materials), rather than a more diversified product line throughout the dental space. I have spoken to a representative from the company, and my limited understanding is that it seems likelier that they plan to stay focused in this segment of dental health for the foreseeable future.

My question would be as follows: given the limited amount of time they have existed as a stand-alone company, can enough be gleaned from what is publicly available to make an informed decision regarding their longer-term prospects? At this point, I only have the worm’s-eye view (I use their products and like them, as well as their clinical support system), and I could really use a bird’s-eye vantage point. Thanks so much, and I look forward to reading you comments!